The effect of canceroembryonic antigen on cytokine production by immunocompetent blood cells in patients with breast cancer

Aim. Investigation of the influence of canceroembryonic antigen (CEA) on the immune cells in patients with breast tumors.

Materials and methods. Peripheral blood of 67 patients with invasive ductal carcinoma (n = 44), fibroadenoma (n = 12) and breast pre-cancer (n = 11). In the supernatants of the blood cells cytokine production induced by CEA was determined by ELISA.

Results. It was found that CEA stimulated production of IL-6, IL-8, IL-10, IL-1β, IL-1Ra, TNFα, G-CSF, GM-CSF and the protein MCP-1 by blood immune cells in patients with fibroadenoma compared with groups of patients with invasive ductal carcinoma and precancerous lesions. Stimulation index of CEA on cytokine production by immunocompetent cells in patients in these groups was lower than in groups of patients with fibroadenoma due to initially high levels of spontaneous cytokine production.

Results.  In  patients  with  fibroadenoma  CEA  was  found  to  stimulate  the  production  of  IL-6,  IL-8,  IL-10,  IL-1β,  IL-1Ra,  TNFa,  G-CSF,  GM-CSF  and  MCP-1  compared  with  groups  of  patients  with  invasive ductal carcinoma and precancerous conditions. Indexes of the influence of CEA on cytokine production by immunocompetent cells in these groups was lower than in the fibroadenoma due to initially high spontaneous production of cytokines.

Conclusion.  Evident  spontaneous  cytokine-producing  function  of  immunocompetent  blood  cells  was revealed in patients with invasive ductal carcinoma and precancerous conditions compared to patients with fibroadenoma.  The  differences  between  the  indices  of  CEA  influence  on  cytokine  production  in  patients with malignant, benign and precancerous conditions can serve as a basis for the development of methods of differential diagnosis of breast tumors.

1. Pavlopoulou A., Scorilas A. A comprehensive phylogenetic and structural analysis of the carcinoembryonic antigen (CEA) gene family. Genome Biol. Evol. 2014; 6 (6): 1314–1326. DOI: 10.1093/gbe/evu103.

2. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clinical Chemistry. 2001; 47 (4): 624–630. http://clinchem.aaccjnls.org/content/47/4/624.full

3. Gataullin I.G., Petrov S.V., Valiev A.A., Shakirov R.K. Prognostic model of treatment efficacy of colorectal cancer patients. Povolzhsky onkologichesky vestnik – Oncology Bulletin of the Volga Region. 2010; 1 (1): 27–30 (in Russ.). http://elibrary.ru/item.asp?id=23498987.

4. Deng K., Yang L., Hu B., Wu H., Zhu H., Tang C. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. Plos. One. 2015; 10: e124151. DOI: 10.1371/journal.pone.0124151.

5. Kim C.H., M.D., Lee S.Y., Kim H.R., Kim Y.J. Prognostic effect of pretreatment serum carcinoembryonicantigen level: a useful tool for prediction of distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and total mesorectal excision. Medicine. 2015; 94 (31): 1–7. DOI: 10.1097/MD.0000000000001291.

6. Wang J., Wang X., Yu F., Chen J., Zhao S., Zhang D., Yu Y., Liu X., Tang H., Peng Z. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically. Int. J. Clin. Exp. Pathol. 2015; 8 (11): 14853–14863. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713601

7. Grunnet M., Sorensen J.B. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012; 76 (2): 138–143. DOI: 10.1016/j.lungcan.2011.11.012.

8. Wang J.Y., Lu C.Y., Chu K.S., Ma C.J., Wu D.C., Tsai H.L., Yu F.J., Hsieh J.S. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur. Surg. Res. 2007; 39: 245–250. DOI: 10.1159/000101952.

9. Bhatt A.N., Mathur R., Farooque A., Verma A., Dwarakanath B.S. Cancer biomarkers−current perspectives. Indian J. Med. Res. 2010; 132: 129–149. http://www.ijmr.org.in/downloadpdf.asp?issn=0971-5916;year=2010;volume=132;issue=2;spage=129;epage=149;aulast=Bhatt;type=2.

10. Lee J.S., Park S., Park J.M., Cho J.H., Kim S.I., Park B.W. Elevated levels of preoperative CA 15–3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann. Oncol. 2013; 24: 1225–1231. DOI: 10.1093/annonc/mds604 PMID: 232301379.

11. Pedersen A.C., Sorensen P.D., Jacobsen E.H., Madsen J.S., Brandslund I. Sensitivity of CA 15–3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin. Chem. Lab. Med. 2013; 51 (7): 1511–1519. DOI: 10.1515/cclm-2012-0488 PMID: 23403727.

12. Wu S.G., He Z.Y., Zhou J., Sun J.Y., Li F.Y., Lin Q., Guo L., Lin H.X. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014; 23: 88–93. DOI: 10.1016/j.breast.2013.11.003 PMID: 24291374.

13. Wu L., Huang P., Wang F., Li D., Xie E., Zhang Y., Pan S. Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer. Ann. Transl. Med. 2015; 3 (21): 328–331. DOI: 10.3978/j.issn.2305-5839.2015.11.17.

14. Hashiguchi Y., Kasai M., Fukuda T., Ichimura T., Yasui T., Sumi T. Serum carcinoembryonic antigen asa tumour marker in patients with endometrial cancer. Curr. Oncol. 2016; 23 (5): e439–e442. DOI: 10.3747/co.23.3153.

15. Barak V., Meirovitz A., Leibovici V., Rachmut J., Peretz T., Eliashar R., Gross M. The diagnostic and prognosticn value of tumor markers (CEA, SCC, CYFRA 21-1, TPS) in head and neck cancer patients. Anticancer Res. 2015; 35 (10): 5519–5524. http://ar.iiarjournals.org/content/35/10/5519.long.

16. Saito H., Noji T., Okamura K., Tsuchikawa T., Shichinohe T., Hirano S. A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma. Surgery. 2016; 159 (3): 842–851. DOI: 10.1016/j.surg.2015.10.027.

17. Liska V., Treska V., Skalicky T., Fichtl J., Bruha J., Vycital O., Topolcan O. , Palek R., Rosendorf J., Polivka J., Holubec L. Evaluation of tumor markers and their impact on prognosis in gallbladder, bile duct and cholangiocellular carcinomas - a pilot study. Anticancer Res. 2017; 37 (4): 2003–2009. DOI: 10.21873/anticanres.11544.

18. Tomita M., Ayabe T., Chosa E., Nose N., Nakamura K. Prognostic significance of a tumor marker index based on preoperative serum carcinoembryonic antigen and Krebs von den Lungen-6 levels in non-small cell lung cancer. Asian Pac. J. Cancer Prev. 2017; 18 (1): 287–291. DOI: 10.22034/APJCP.2017.18.1.287.

19. Kim C.G., Ahn J.B., Jung M., Beom S.H., Heo S.J, Kim J.H., Kim Y.J., Kim N.K., Min B.S., Koom W.S., Kim H., Roh Y.H., Ma B.G., Shin S.J. Preoperative serum carcinoembryonic antigen level as a prognostic factor for recurrence and survival after curative resection followed by adjuvant chemotherapy in stage III colon cancer. Ann. Surg. Oncol. 2017; 24 (1): 227–235. DOI: 10.1245/s10434-016-5613-5.

20. Gangopadhyay A., Lazure D., Thomas P. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells. Clin. Exp. Metastasis. 1998; 16 (8): 703–712. https://www.ncbi.nlm.nih.gov/pubmed/10211983.

21. Semiglazov V.F., Ailamazyan E.K., Bailyuk Ye.N., Niauri D.A., Ivanov V.G., Manikhas A.G., Kvetnoi I.M., Soshnev A.A. Prophylaxis of breast cancer in patients with hyperproliferative pathologies of reproductive system. Voprosy onkologii – Problems in Оncology. 2006; 52 (3): 247–257 (in Russ.). http://elibrary.ru/item.asp?id=13003090.

22. Pathologic anatomy: national guidance; рod. red. M.A. Paltseva. М.: GEOTAR-Media Publ., 2014: 1264 (in Russ.).

23. Kunts T.A., Karpukhina K.V., Mikhailova E.S., Varaksin N.A., Morozov D.V., Autenshlyus A.I. Cytokine-producing potential of blood cells in invasive ductal cancer and breast fibroadenoma. Tsitokiny i vospalenie – Cytokines and Inflammation. 2015; 14 (3): 47–52 (in Russ.). http://elibrary.ru/item.asp?id=26511107.

24. Kunts T.A., Karpukhina K.V., Mikhaylova E.S., Varaksin N.A., Autenshlyus A.I. Cytokine pattern of supernatant of blood immunocompetent cells and tumor at invasive ductal carcinoma of the breast. Sovremennye problemy nauki i obrasovaniya – Modern Problems of Science and Education. 2016; 5: 103 (in Russ.). https://science-education.ru/ru/article/view?id=25296.

25. Visscher D.W., Nassar A., Degnim A.C., Frost M.H., Vierkant R.A., Frank R.D., Tarabishy Y., Radisky D.C., Hartmann L.C. Sclerosing adenosis and risk of breast cancer. Breast Cancer Res. Treat. 2014; 144 (1): 205–212. DOI: 10.1007/s10549-014-2862-5.

26. Cichon M.A., Degnim A.C., Visscher D.W., Radisky D.C. Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J. Mammary Gland Biol. Neoplasia. 2010; 15 (4): 389–397. DOI: 10.1007/s10911-010-9195-8.